There are better stocks to buy instead of Nvidia (NASDAQ: NVDA ). Although the chipmaker has been an absolute workhorse and promises to radically alter the artificial intelligence landscape, let’s be real and admit NVDA stock is not cheap. The leading AI stock trades at 64 times earnings, 34 times sales, and 70 times free cash flow (FCF). Those are all nose-bleed valuations. Essentially, if you were to buy Nvidia outright, it would take you 64 years to earn back your investment through its profits. As the popular meme says, ain’t nobody got time for that! That’s why I say there are better stocks to buy instead of Nvidia. The chipmaker is an excellent company, but there is concern that the melt-up in AI stocks may have run too far too fast. NVDA stock has fallen 22% from its recent high. As the market rotates away from former high-flying tech stocks , the following three companies just might be better for your portfolio. DaVita (DVA) Source: APN Photography / Shutterstock.com Dialysis treatment center DaVita (NYSE: DVA ) is one of the two largest dialysis centers in the U.S.

No summary available.

Fresenius Medical Care (FMS) has released an update. Fresenius Medical Care AG, a company specializing in medical care products and services includ…

Fresenius Medical Care CEO Helen Giza comments on the firm''s second-quarter earning results.

Organic revenue growth of +2.3% supported by both segments Care Delivery and Care Enablement Operating income1 and operating income margin1 increase driven by Care Enablement Additional FME25 savings of EUR 57 million achieved and on track to reach the upper end of the full year savings…

Fresenius Medical Care reports Q2 2024 growth: 2.3% organic revenue increase, 19% operating income boost, and improved margins. Learn how strategic initiatives are driving the company''s turnaround and financial performance.

Fresenius Medical Care (FMS) has released an update. Fresenius Medical Care has reported progress in its financial performance for the second quart…

BAD HOMBURG, Germany (AP) — BAD HOMBURG, Germany (AP) — Fresenius Medical Care AG (FMS) on Tuesday reported second-quarter profit…

We predict a promising future for Fresenius Medical despite volatility, citing revenue growth, cost savings, and market leadership. See why FMCQF stock is a buy.

The U.S. Federal Trade Commission (FTC) is investigating healthcare providers DaVita and Fresenius Medical Care over allegations that the companies have been illegally thwarting smaller competitors, Politico reported on Saturday, citing three people familiar with the matter.